<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> predisposition syndrome classically caused by germline mutations of the mismatch repair genes, MLH1, MSH2, MSH6 and PMS2 </plain></SENT>
<SENT sid="1" pm="."><plain>Constitutional epimutations of the MLH1 gene, characterized by soma-wide methylation of a single allele of the promoter and allelic transcriptional silencing, have been identified in a subset of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> cases lacking a sequence mutation in MLH1 </plain></SENT>
<SENT sid="2" pm="."><plain>We report two individuals with no family history of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> who developed that disease at age 18 and 20 years </plain></SENT>
<SENT sid="3" pm="."><plain>In both cases, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> had arisen because of the de novo occurrence of a constitutional MLH1 epimutation and somatic loss-of-heterozygosity of the functional allele in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We show for the first time that the epimutation in one case arose on the paternally inherited allele </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of 13 tumors from seven individuals with constitutional MLH1 epimutations showed eight <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had lost the second MLH1 allele, two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had a novel pathogenic missense mutation and three had retained heterozygosity </plain></SENT>
<SENT sid="6" pm="."><plain>Only 1 of 12 tumors demonstrated the BRAF V600E mutation and 3 of 11 tumors harbored a mutation in KRAS </plain></SENT>
<SENT sid="7" pm="."><plain>The finding that epimutations can originate on the paternal allele provides important new insights into the mechanism of origin of epimutations </plain></SENT>
<SENT sid="8" pm="."><plain>It is clear that the second hit in MLH1 epimutation-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> typically has a genetic not epigenetic basis </plain></SENT>
<SENT sid="9" pm="."><plain>Individuals with mismatch repair-deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> without the BRAF V600E mutation are candidates for germline screening for sequence or methylation changes in MLH1 </plain></SENT>
</text></document>